Harnessing Stem Cell-Derived EVs for Severe Skin Conditions

In this first segment of Cell & Gene Live, Redefining CGT with Exosomes and EVs, Dr. Gloria Matthews, CMO at Aegle Therapeutics explains how the company is pioneering the use of bone marrow-derived mesenchymal stem cell extracellular vesicles (EVs), including exosomes and apoptotic bodies, to promote regenerative healing and modulate inflammation in severe dermatological conditions. With a focus on improving both cosmetic and functional outcomes, their lead program targets deep second-degree burns and rare diseases like epidermolysis bullosa (EB), where early results show promising wound closure and potential immune modulation beyond what gene therapy alone can offer. The company’s proteomic analysis supports a consistent therapeutic profile across EV batches, setting their platform apart in the cell and gene therapy space.